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A B S T R A C T
Increased serum angiotensin-converting enzyme (SACE) activity and serum concentration of endothelin-1 (ET-1)
were found in liver cirrhosis. We investigated a correlation between the different stages of liver fibrosis and SACE activ-
ity and serum ET-1 concentration. Seventy patients with pathohistologically established chronic liver disease were di-
vided in three groups according to Ishak criteria for liver fibrosis: minimal fibrosis (Ishak score 0–1, n=20), medium fi-
brosis (Ishak score 2–5, n=20) and cirrhosis (Ishak score 6, n=30). SACE activity and ET-1 concentration were
determined using commercial ELISA kits. SACE activity and ET-1 concentrations were proportional to the severity of
disease, the highest being in patients with liver cirrhosis. Maximal increase in SACE activity was found between mini-
mal and medium fibrosis while maximal increase in ET-1 concentration was revealed between medium fibrosis and cir-
rhosis. The analysis of the Receiver Operating Characteristic (ROC) curve for SACE activity suggested a cut-off value to
separate minimal from medium fibrosis at 59.00 U/L (sensitivity 100%, specificity 64.7%). The cut-off value for serum
ET-1 concentration to separate medium fibrosis from cirrhosis was 12.4 pg/mL (sensitivity 96.8%, specificity 94.4%). A
positive correlation between SACE activity and ET-1 concentration was registered (Spearman’s ñ=0.438, p=0.004). Both
SACE activity and ET-1 concentration were increased in all stages of liver fibrosis. Cut-off points for SACE activity and
ET-1 concentration could be a biochemical marker for the progression of fibrosis. Positive correlation between SACE ac-
tivity and ET-1 concentration might indicate their interaction in the development of liver cirrhosis.
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Introduction
Liver fibrosis is a common consequence of chronic
liver injury regardless of its etiology. Advanced fibrosis
disrupts the normal liver architecture, causing hepato-
cellular dysfunction and portal hypertension1. Hepato-
stellate cells (HSC) have an important role in the regu-
lation and modulation of hepatic blood flow through
growth factor secretion, retinoid storage and the release
and production of extracellular matrix of space of Disse1.
After liver injury, HSC undergo a phenotypic transforma-
tion to become myofibroblast-like with expression of
á-smooth muscle actin an secretion of the extracellular
matrix composed of various proteoglycans and proteins
such as collagen type I1. Also, HSC activation includes in-
creased expression of receptors for a variety of vasocon-
strictor substances, such as angiotensin II (AT-II) and
endothelin (ET-1)2–4. These afore mentioned changes are
associated with the modulation of extracellular matrix
production and fibrogenesis governed by HSC2–4.
Previously, it has been observed that serum angioten-
sin-converting enzyme (SACE) activity, which mediates
AT-II production, and serum ET-1 concentration were in-
creased in the patients with chronic liver diseases, for ex-
ample: chronic viral hepatitis B and C, non-alcoholic liver
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disease and liver cirrhosis5–7. Moreover, AT II and ET-1
have a leading role in the progression of chronic liver
damage by up-regulation of extracellular matrix produc-
tion and fibrogenesis2–4. However, to date, there are no
studies about the activity of the mentioned parameters
regarding the severity of liver fibrosis. The aim of this
study was to analyze the SACE activity and serum ET-1
concentrations in the patients with chronic liver disease
regarding the stages of liver fibrosis.
Patients and Methods
Study design
The prospective observational study was conducted
from April 2002 to September 2004 in the Division of
Gastroenterology and Hepatology, Dubrava University
Hospital, Zagreb, Croatia. The 70 patients (42 men;
mean age 52.00±16.46 years) with different stages of
chronic liver disease were enrolled in the study. Patients
suffering from the diseases in which SACE activity or
ET-1 concentration might be changed (e.g. diabetes me-
llitus, hypertension, hyperthyroidism, sarcoidosis, silico-
sis, lung cancer, hepatocellular carcinoma, asthma, ob-
structive icterus, hypothyroidism, bacterial peritonitis,
and other infectious diseases) were excluded from study.
The study was conducted according to the principles of
the Declaration of Helsinki and approved by the hospital
ethics committee. All participants enrolled in the study
gave informed consent.
Diagnosis of liver disease was established on the basis
of clinical and biochemical means, ultrasonography and
CT scan of the abdomen, and histological findings of liver
bioptate. The stage of chronic liver disease was estab-
lished through pathohistological examination of liver
bioptate obtained under the ultrasonographic control.
Patients were divided in three groups according to
Ishak criteria for fibrosis8: minimal fibrosis (Ishak score
0–1, n=20), medium fibrosis (Ishak score 2–5, n=20),
and cirrhosis (Ishak score 6, n=30).
Measurement of serum ET-1 concentration
The plasma ET-1 concentration was determined with
enzyme linked immunosorbent assay (ELISA) using com-
mercial kit »Endothelin ELISA« (Biomedica, Vienna,
Austria) and ELx800 universal Plate Reader, Bio-Tek In-
struments Inc. This is a sandwich assay which recognizes
following epitopes on ET-1: coating-antibody recognizes
amino acids 16–21, while detection-antibody recognizes
amino acids 8–16. Detection-antibody is conjugated with
peroxidase which catalyzes degradation of tetramethyl-
benzidine, and this reaction is accompanied by color
change detec± on an ELISA reader. The amount of devel-
oped color is directly proportional to the amount of ET-1
in the sample, expressed in pg/mL.
Measurement of SACE
The SACE activity was determined with enzyme lin-
ked immunosorbent assay (ELISA) using commercial kit
»InfinityTM ACE Liquid Stable Agent« (Thermo Electron
Corporation, New York, USA). This kit utilizes the cata-
lytic activity of ACE in the following reaction: furylacry-
loylphenylalanineglyclglycine (FAPGG) ® furylacryloyl-
phenylalanine (FAP) + glyclglycine (GG). Hydrolysis of
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TABLE 1
EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF THE STUDY POPULATION REGARDING THE STAGE OF LIVER FIBROSIS







Ishak score 0–1 2–5 6
Female/Male (No. of pts) 9/11 8/12 11/19
Age (years) 52 (19–69) 52 (33–75) 52 (24–72)




Hepatitis B and C (1)
Alcoholic hepatitis (6)
Primary biliary cirrhosis (3)
Alcoholic hepatic cirrhosis (30)
Ascites (No. of pts) 0 0 0
Sodium (mmol/L) 142 (126–151) 140 (132–145) 138 (128–143)
Potassium (mmol/L) 4.3 (3.4–5.2) 4.2 (3.6–5.2) 4.2 (2.4–7.2)
Amoniac (mmol/L) 12 (3–71) 21 (11–99) 61 (12–110)
Bilirubine (mmol/L) 11.9 (7.8–61.3) 19.1 (5.2–198.1) 63.3 (8.8–518.6)
BUN (mmol/L) 5.8 (3.6–11.3) 5.3 (3.4–11.9) 7.5 (3.6–22.1)
Creatinin (mmol/L) 78 (24–94) 80 (43–167) 83 (52–277)
Albumins (g/L) 49 (35–53) 47 (32–53) 41 (23–51)
Prothrombin time(%) 91 (37–106) 69 (42–97) 54 (10–99)
FAPGG results in decrease in absorbance at 340 nm. The
SACE activity in the sample is determined by comparing
the sample reaction rate to that obtained with the ACE
Calibrator, and the results were expressed in IU/L. All
the measurements were performed on Olympus AU-
-CONNECTOR 27000 (Olympus, Japan).
Statistics
Since Kolmogorov-Smirnov test did not show normal
distribution of the variables, SACE activity and serum
concentration of ET-1 in three different groups were
summarized by median and range. Cut-off values of
SACE activity and serum concentration of ET-1 between
groups were determined by the Receiver Operating Cha-
racteristic (ROC) curve analysis. Correlation between
SACE activity and serum concentration of ET-1 was ana-
lyzed through Spearman’s test of rank correlation, fol-
lowed by linear regression analysis. All statistical analy-
ses were performed using MedCalc for Windows (v.7.5.
Frank Schoonjans Inc., Mariakerke, Belgium).
Results
Demographic and clinical variables in study popula-
tion are presented in Table 1. The values of ammonia and
bilirubin were progressively increased with regard to the
stage of liver disease, the highest being in patients with
liver cirrhosis. On the contrary, the value of prothrombin
time was gradually decreased with regard to the progres-
sion of liver disease, the lowest being in patients with
liver cirrhosis. There were no differences in the other de-
mographic and clinical variables.
The SACE activity was increased in proportion with
liver fibrosis (Figure 1). The lowest SACE activity was
found in the patients with minimal disease (median 57
IU/L, range 16–94 IU/L), while the highest activity was
observed in the patients with liver cirrhosis (median 89,
range 65–139 IU/L). Serum concentrations of ET-1 sho-
wed a similar trend (Figure 2). Namely, the lowest ET-1
concentrations (median 6.25, range 2.38–11.80 pg/mL)
were observed in patients with minimal disease, while in
patients with cirrhosis, the highest ET-1 concentrations
(median 18.95, range 12.05–59.38 pg/mL) were regis-
tered. In addition, there was the positive correlation be-
tween SACE activity and serum concentration of ET-1
(Spearman’s p=0.438, p=0.004; Figure 3).
Since the elevation of SACE activity and ET-1 concen-
trations did not follow the progression of liver fibrosis in
a linear manner. The highest increase in SACE was ob-
served in the progression from minimal to moderate fi-
brosis, while the highest increase in serum ET-1 concen-
tration was observed during the progression from me-
dium fibrosis to liver cirrhosis. Therefore, we tried to de-
termine cut-off values for both variables using ROC
curve analysis. The analysis of the ROC curve for SACE
activity determined a cut-off value to separate minimal
fibrosis from medium fibrosis at 59.00 U/L, with a sensi-
tivity of 100%, and a specificity of 64.7% (Figure 4). The
cut-off value for serum ET-1 concentration to separate
medium fibrosis from cirrhosis was 12.4 pg/mL, with a
sensitivity of 96.8% and a specificity of 94.4% (Figure 5).























Fig. 1. Serum angiotenzin-converting enzyme (ace) activity in pa-






















Fig. 2. Serum concentration of endothelin-1 (et-1) in patients with
minimal fibrosis, medium fibrosis and cirrhosis.
Fig. 3. Dissociation between serum angiotezin-convertin enzyme
(ace) activity and serum concentration of endothelin -1 in pa-
tients with minimal fibrosis, medium fibrosis and cirrhosis.
Discussion and Conclusion
The main findings of our study are: 1) both SACE ac-
tivity and serum concentration of ET-1 are increased in
patients with chronic liver disease in proportion with the
stage of liver fibrosis, 2) there is positive correlation be-
tween SACE activity and ET-1 concentration in this
group of patients, and 3) SACE activity and ET-1 serum
concentration could be valuable laboratory markers for
determining progression of liver disease from mild fibro-
sis into cirrhosis.
Previously, it has been observed that SACE activity
was increased in the patients with chronic liver diseases
– e.g. chronic viral hepatitis B and C, non-alcoholic liver
disease and liver cirrhosis5–7. The exact mechanism of
the increase of the SACE activity found in these patients
is not clear yet. The possible causes could be decreased
inactivation of this enzyme caused by diminished lung
function in cirrhosis, ACE hyper production in the spleen,
hypoxia and electrolyte disbalans caused by hemody-
namic changes9–11. Additionally, these patients show ele-
vated concentrations of histamine, a substance that in-
creases the secretion of ACE from blood vessel endothelial
cells10,11. On the other hand, using the model of chronic
liver damage caused by the ligation of biliary ducts,
Paizis et al. showed increased ACE secretion from acti-
vated HSC, phagocytes, and proliferating epithelial cells
of biliary ducts12.
Increased activation of tissue and intracellular renin-
-angiotensin-aldosterone system (RAAS) in chronically
damaged liver, as well as the increased ACE activity in lo-
cal circulation, lead to increased serum concentration of
AT-II13–16. Bataller et al. demonstrated that activated
HSC expressed AT-1 subtype of AT II receptors17. They
also showed that binding of AT-II to these receptors in-
duced contraction and proliferation of HSC17. This study
implies that AT-II is a mitogenic factor for activated
HSC, which could play a role in the pathogenesis of
intrahepatic portal hypertension due to its effects on
HSC17. It has been reported that AT-II induced the secre-
tion of the vascular endothelial growth factor (VEGF) in
a dose-dependent manner18. The hepatic VEGF level in
chronic liver diseases has been shown to be increased
with disease progression, and it stimulated HSC activa-
tion and sinusoidal capillarization18. Besides its other ef-
fects, AT II is a powerful simulator of ET-1 production in
chronic liver disease, which could be a possible explana-
tion of the positive correlation between SACE activity
and ET-1 concentration observed in our study19.
On the other hand, the elevation of serum ET-1 con-
centration that we found in all our patients is probably
due to the diminished catabolism and elimination of
ET-1, or increased synthesis and secretion that occur in
chronic liver damage. The lungs have an important role
in the clearance of ET-120. Therefore, it is possible that in
liver cirrhosis intrahepatic shunts cause the diminish-
ment of lung clearance of ET-120. Additionally, the kidney
clearance of ET-1 is also changed, mainly as the conse-
quence of lower activity of the enzymes that metabolize
it, such as neural endopeptidase21,22. On the other side,
increased production of ET-1 in the splanchnic pool in
the patients with liver cirrhosis represents an additional
load for already slowed liver elimination (due to reduced
functional liver tissue by fibrosis) 23. In liver cirrhosis,
there is a significantly increased production of ET-1 in
the endothelial and smooth muscle cells of splanchnic
blood vessels, as well as in the intestinal mucosal cells23,24.
This is a response to hypoxia, oxidative stress, bacterial
endotoxemia, and increased activation of systemic RAAS/
AT II25,26. Since the endotoxin levels are proportionally
elevated in more severe liver damage, especially in cir-
rhosis, endotoxemia could be another mechanism of ET-1
increment in liver cirrhosis23.
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Fig. 4. The analysis of the roc curve for serum angiotenzin-con-
verting enzyme (sace) activity in patients with minimal fibrosis,
medium fibrosis and cirrhosis. A cut-off value determined to sep-
arate early from medium fibrosis was 59.00 U/L, with the sensi-
tivity of 100%, and specificity of 64.7%.
Fig. 5. The analysis of the roc curve for serum concentration of
endothelin-1 (et-1) in patients with minimal fibrosis, medium fi-
brosis and cirrhosis. A cut-off value determined to separate me-
dium fibrosis from cirrhosis was 12.4 pg/mL, with the sensitivity
of 96.8%, and specificity of 94.4%.
Elevated ET-1 serum concentration found in the pa-
tients with progressive liver damage has a vasoconstric-
tive effect in the sinusoidal endothelial cells and acti-
vated HSC. This significantly worsens the hemodynamic
condition in the damaged liver. At the same time, in acti-
vated HSC ET-1 induces production of the extracellular
matrix significantly more than AT-II. ET-1 enhances the
development of liver fibrosis and its progression into
cirrhosis27,28.
In the presented study both SACE activity and ET-1
serum concentration were increased in all groups of pa-
tients with liver disease. Moreover, values of both param-
eters were proportional to the severity of the disease, the
highest being in patients with liver cirrhosis. However,
the highest increase of SACE activity was accompanied
with the progression from minimal to moderate fibrosis,
while the highest increase in serum ET-1 concentration
was observed during the progression from moderate fi-
brosis to cirrhosis. In that context, the analysis of the
ROC curve set 59.00 U/L to be a cut-off value for SACE
activity which could separate minimal from medium fi-
brosis, while the same analysis pointed out serum ET-1
concentration of 12.4 pg/mL as a cut-off value which indi-
cates the progression from medium fibrosis into cirrho-
sis. The positive correlation of SACE activity and serum
ET-1 concentration observed in our study suggests the
possibility that the increase of serum ET-1 concentration
partially might be the result of the increased ET-1 pro-
duction in HSC and endothelial sinusoidal cells stimu-
lated with AT II. Thus, it could be speculated that sup-
pression of the SACE activity (e.g. with using ACE in-
hibitors) may result in decreases of serum ET-1 con-
centration and slower progression of liver fibrosis into
cirrhosis.
In conclusion, both SACE activity and serum concen-
tration of ET-1 are increased in patients with chronic
liver disease in proportion with the stage of liver fibrosis.
SACE and serum ET-1 concentration could be additional
serum markers in the non-invasive »staging« of chronic
liver disease. Further studies are needed to elucidate the
possible correlation between staging of liver fibrosis,
SACE activity and ET-1 concentrations and changes in
liver blood flow, which could imply therapeutic interven-
tions aimed at the modulation of the effect of vasoactive
substances.
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KONCENTRACIJA ENDOTELINA-1 I AKTIVNOST ANGIOTENZIN-KONVERTIRAJU]EG ENZIMA U
ODNOSU NA STUPANJ JETRENE FIBROZE
Pove}ana aktivnost angiotenzin-konvertiraju}eg enzima (SACE) i serumska koncentracija endotelina-1 (ET-1) za-
bilje`ene su u bolesnika s cirozom jetre. U na{em smo istra`ivanju korelirali aktivnost SACE i serumsku koncentraciju
ET-1 s razli~itim stadijima jetrene fibroze. Sedamdeset bolesnika s patohistolo{ki potvr|enom kroni~nom bole{}u jetre
podijeljeno je u tri skupine prema Ishakovim kriterijima za fibrozu jetre: minimalna fibroza (Ishakov skor 0–1, n=20),
umjerena fibroza (Ishakov skor 2–5, n=20) i ciroza (Ishakov skor 6, n=30). Aktivnost SACE i koncentracija ET-1 odre-
|ene su primjenom komercijalnih ELISA kitova. Aktivnost SACE i koncentracija ET-1 bile su proporcionalne te`ini
bolesti; najve}e vrijednosti zabilje`ene su u bolesnika s cirozom jetre. Najve}i porast aktivnosti SACE je zabilje`en na
prijelazu minimalne u umjerenu fibrozu, dok je najve}i porast koncentracije ET-1 zabilje`en na prijelazu iz umjerene
fibroze u cirozu. Analiza ROC krivulje za aktivnost SACE sugerira vrijednost od 59,00 u/l kao razdjelnicu izme|u mini-
malne i umjerene fibroze (osjetljivost 100%, specifi~nost 64,7%). Vrijednost koncentracije serumskog ET-1 od 12,4 pg/mL
sugerirana je kao razdjelnica umjerene fibroze i ciroze jetre (osjetljivost 96,8%, specifi~nost 94,4%). Zabilje`ena je po-
zitivna korelacija izme|u aktivnosti SACE i koncentracije ET-1 (Spearmanov koeficijent korelacije p=0,438, p=0,004).
Aktivnost SACE i koncentracija ET-1 mogu poslu`iti kao biokemijski biljezi za pra}enje napredovanja fibroze jetre.
Pozitivna korelacija izme|u aktivnosti SACE i koncentracije ET-1 mo`e ukazivati na njihovu interakciju u razvoju
ciroze jetre.
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